Additionally, improving CAR-T biological efficiency could reduce dosing needs, further cutting costs and expanding access.

When even one tiny section of a person’s genetic code becomes mutated or modified, cells can begin to act out of ...

CROs can contribute to site collaboration by also identifying and supporting non-academic institutions capable of conducting ...

INmune Bio (NASDAQ:INMB) announced a partnership with the Cell and Gene Therapy Catapult, a UK-based innovation center ...

After exploring a rival buyout offer worth 50% more than its first, bluebird bio is back where it started. | After striking ...

At the GenScript Biotech Global Forum 2025, industry leaders celebrated CAR T cell therapy achievements while discussing ...

The major workforce overhaul comes a month after parent company Roche deemed the cell and gene therapy firm a financial loss.

A new collaboration facility, opened by Thermo Fisher Scientific, will work to make cell therapy developers’ research more accessible and optimized.

Bluebird Bio and Xcellbio have entered into an agreement to support the commercialization of sickle cell gene therapy ...

INmune Bio (INMB) has partnered with the Cell and Gene Therapy Catapult to establish large-scale, commercial-ready manufacturing for its cell ...

Feb. 7, 2025 — A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 ...

Following CORDStrom TM, INmune Bio plans to transition production of INKmune ®, its NK-priming cell medicine for solid tumors, to the same facility, supporting ongoing and future trials in the US and ...